Lapatinib Ditosylate API

Name	Lapatinib ditosylate
Chinese name	二甲苯磺酸拉帕替尼
Cas Number	388082-78-8
Source	India
Qualifications	USDMF/-/-/-/-

Lapatinib xylene sulfonate was originally developed as GlaxoSmithKline, and was approved for marketing by the US Food and Drug Administration (FDA) in 2007. Lapatinib is an inhibitor of HER-1/HER-2 tyrosine kinase and is the second breast cancer molecular targeted new drug after trastuzumab. It can inhibit receptor autophosphorylation and block Disconnect downstream signal pathways and promote tumor cell apoptosis. It can be used to treat metastatic or advanced breast cancer and metastatic breast cancer that is associated with hormone-receptor positive in women after menopause. Studies have confirmed that it is effective against trastuzumab-resistant tumors. The 2008 NCCN breast cancer clinical practice guidelines recommended the second-line anti-HER2 therapy after trastuzumab failure, that is, lapatinib combined with capecitabine.

Hot Tags: lapatinib ditosylate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Brinzolamide API, Gabapentin API, Letrozole API, Fondaparinux API, Celecoxib API, Teriflunomide API

• Previous: Tippyridine Hydrochloride API
• Next: Pabxilib API